Immunome Inc. (IMNM): Price and Financial Metrics
IMNM Price/Volume Stats
| Current price | $14.97 | 52-week high | $30.96 |
| Prev. close | $14.69 | 52-week low | $4.50 |
| Day low | $14.39 | Volume | 817,900 |
| Day high | $15.02 | Avg. volume | 740,589 |
| 50-day MA | $21.24 | Dividend yield | N/A |
| 200-day MA | $12.79 | Market Cap | 897.35M |
IMNM Stock Price Chart Interactive Chart >
Immunome Inc. (IMNM) Company Bio
Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.
Latest IMNM News From Around the Web
Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.
Immunome to Present at the Stifel 2023 Healthcare ConferenceSEATTLE & EXTON, Pa., November 10, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET. |
Immunome Reports Third Quarter 2023 Financial ResultsSEATTLE & EXTON, Pa., November 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. |
Immunome Appoints Jean-Jacques Bienaimé to Board of DirectorsSEATTLE & EXTON, Pa., November 08, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques "JJ" Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals. |
7 Biotech Stocks to Get In Now Before Investors Catch OnBiotech stocks are down, but there are hidden gems among the rubble. |
Immunome Appoints Bob Lechleider, M.D., as Chief Medical OfficerSEATTLE & EXTON, Pa., October 19, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research. |
IMNM Price Returns
| 1-mo | -30.69% |
| 3-mo | -8.10% |
| 6-mo | 71.09% |
| 1-year | 165.90% |
| 3-year | -38.70% |
| 5-year | N/A |
| YTD | 39.91% |
| 2023 | 384.16% |
| 2022 | -82.95% |
| 2021 | 33.88% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...